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SMAD4 constrains progression of Pten-null prostate can-
cer and serves as a common downstream node of trans-
forming growth factor β (TGFβ) and bone morphogenetic
protein (BMP) pathways. Here, we dissected the roles of
TGFβ receptor II (TGFBR2) and BMP receptor II
(BMPR2) using a Pten-null prostate cancer model. These
studies demonstrated that the molecular actions of
TGFBR2 result in both SMAD4-dependent constraint of
proliferation and SMAD4-independent activation of apo-
ptosis. In contrast, BMPR2 deletion extended survival rel-
ative toPtendeletionalone, establishing itspromoting role
in BMP6-driven prostate cancer progression. These analy-
ses reveal the complexity ofTGFβ–BMPsignaling and illu-
minate potential therapeutic targets for prostate cancer.
Supplemental material is available for this article.
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Prostate cancer (PCa) is the most commonly diagnosed
malignancy and the third leading cause of cancer mortal-
ity in American men. PCa initiation and progression are
governed by numerous genetic alterations (Shen and
Abate-Shen 2010). Loss of the tumor suppressor PTEN is
a common genetic aberration (Abeshouse et al. 2015;
Robinson et al. 2015). Correspondingly, prostate-specific
Pten deletion in mice produces slowly progressing pros-
tate intraepithelial neoplasia (PIN), which, following a
long latency, can progress to high-grade adenocarcinoma
withminimal invasive andmetastatic potential (Trotman
et al. 2003; Wang et al. 2003). This slowly progressive dis-
ease results from the activation of a senescence program
that can be neutralized by deletion of tumor suppressor
genes p53 (Chen et al. 2005) or Smad4 (Ding et al. 2011).
Of relevance to the present study, prostate-specific dele-
tion of Pten and Smad4 generates rapidly progressive
PCa with metastasis to lymph nodes and the lungs
(Ding et al. 2011; Wang et al. 2016).
The cross-talk between transforming growth factor β
(TGFβ) and bone morphogenetic protein (BMP) signaling
plays critical roles in a number of processes of organogen-
esis andhomeostasis,with the output (antagonistic or syn-
ergistic) beinghighly context-dependent (McDonnell et al.
2001;Lu et al. 2010;Keller et al. 2011;Li et al. 2015). In can-
cer, the TGFβ pathway has long been recognized to exert
opposing roles throughout cancer progression, switching
from anti-tumor to prometastasis mechanisms depending
on cell type and associated genetic alterations, among oth-
er factors (Massagué 2008). In PCa, inactivation the TGFβ
pathway through deletion of TGFβ receptor II (Tgfbr2) can
promote AKT-mediated PCa tumorigenesis (Bjerke et al.
2014), whereas enhanced TGFβ signaling can induce a
pro-bonemetastasis program (Fournier et al. 2015). Adding
to the complexity, TGFβ-regulated responses can bemedi-
ated by several SMAD-independent pathways, best illus-
trated by TGFβ-induced activation of JNK and p38
MAPK to trigger apoptosis (Zhang 2009). With respect to
BMP signaling, various BMP ligands can exert differential
biological impacts on PCa tumorigenesis. For example,
BMP6, which is overexpressed in some human PCa cases,
has been shown to promotemigration and invasion (Darby
et al. 2008) and stimulate PCa growth and resistance to an-
drogen receptor (AR) antagonists (Kwon et al. 2014). In
contrast, BMP7 inhibits PCa cell proliferation (Kobayashi
et al. 2011), although experimental evidence also supports
an anti-apoptotic role (Yang et al. 2005). Moreover, in
breast cancer, organ-specific bioavailability of BMP li-
gandsand their antagonist,Coco, candictate the efficiency
of metastasis (Gao et al. 2012).
The importance of SMAD4 in PCa progression and the
role of SMAD4 as the only common partner (co-SMAD)
for all R-SMADs signaling from specific upstream recep-
tors (Massagué 2008) prompted us to explore the relative
contributions of TGFβ and BMP pathways. We explored
the biological complexity of TGFβ and BMP signaling by
genetic deletion of Tgfbr2 and BMP receptor II (Bmpr2)
in the context of the Pten-null PCa mouse model.
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Results and Discussion
TGFBR2 is a more potent tumor suppressor than SMAD4
in PTEN-null PCa
Our previouswork showed no discernable histological im-
pact on the mouse prostate upon Smad4 deletion using
the prostate-specific Cre transgene (PB-Cre4) (Ding et al.
2011). Similarly, PB-Cre4-directed deletion of Tgfbr2
(Chytil et al. 2002) or Bmpr2 (Beppu et al. 2005) yielded
no histological abnormalities over an observation period
of 9 mo (Supplemental Fig. S1A). In each model, specific
receptor expression loss was confirmed by immunohisto-
chemistry (IHC) (Supplemental Fig. S1B,C). To compare
more precisely the relative impact of SMAD4, TGFBR2,
and BMPR2 deletion on the progression of the Pten-null
PCamodel, we generated the following cohorts and deter-
mined theirmedian survival: PB-Cre+ PtenL/L (55wk), PB-
Cre+ PtenL/L Smad4L/L (16.4 wk), PB-Cre+ PtenL/L
Tgfbr2L/L (12.7 wk), and PB-Cre+ PtenL/L Bmpr2L/L (73.6
wk) (Fig. 1A). These strikingly different outcomes imply
that despite convergence on the SMAD4 node, TGFBR2
and BMPR2 exert opposing actions on PCa development.
We also performed expression characterizations of some
key proteins, including TGFBR2 and BMPR2 levels,
which are comparable in wild-type prostates and PB-
Cre+ PtenL/L tumors (Supplemental Fig. S1B,C). In addi-
tion, AR expression among the prostate epithelial cells
displayed modest variations in each of the four models
compared with wild-type prostates, yet overall loss of
Tgrbr2 or Bmpr2 in PB-Cre+ PtenL/L tumors did not
impact AR expression in any specific direction (Supple-
mental Fig. S2A). As expected, Pten loss resulted in in-
creased phospho-AKT signal, which was not further
impacted by the additional deletion of Smad4, Tgfbr2, or
Bmpr2 (Supplemental Fig. S2B,C). Based on the dramatic
differences in the rate of tumor progression, we focused
on addressing two key questions: how TGFBR2 displays
stronger tumor-suppressive function than SMAD4 in
prostate by comparing PB-Cre+ PtenL/L Smad4L/L and
PB-Cre+ PtenL/L Tgfbr2L/L models and how BMPR2 pro-
motes Pten-deficient prostate tumors by comparing PB-
Cre+ PtenL/L and PB-Cre+ PtenL/L Bmpr2L/L models.
Compared with PB-Cre+ PtenL/L mice, both PB-Cre+
PtenL/L Smad4L/L and PB-Cre+ PtenL/L Tgfbr2L/L showed
more aggressive tumor progression but at different rates.
Therefore, we compared these two models. At 11 wk of
age, most PB-Cre+ PtenL/L Smad4L/L tumors presented
with high-grade PIN, whereas PB-Cre+ PtenL/L Tgfbr2L/L
tumors progressed to adenocarcinomawith local invasion
(Fig. 1B). Next, we compared the impact of TGFBR2 ver-
sus SMAD4 deficiencies on metastasis. To that end, the
two models incorporated the fluorescence reporter
mTmG (Muzumdar et al. 2007), which allows for Cre-de-
pendent GFP expression in prostate epithelia cells. In the
PB-Cre+ PtenL/L Smad4L/L mTmGL/+ model, GFP+ PCa
cells were detected in the draining lymph nodes as early
as 10 wk of age and in the lungs as early as 14 wk of age
(Fig. 1C). In comparison, the PB-Cre+ PtenL/L Tgfbr2L/L
mTmGL/+ model showed disseminated neoplastic cells
to the lymph nodes and the lungs as early as 6 wk of age
(Supplemental Fig. S3A) and exhibited metastases in the
lymph nodes andmicrometastases in the lungs at full pen-
etrance by 10 wk of age (Fig. 1C). In bothmodels, there is a
trend of age-dependent increase of lung micrometastasis,
as enumerated by GFP signals (Fig. 1D). Moreover, it is in-
triguing to note that GFP+ disseminated cancer cells are
observed in mice with high-grade PIN, consistent with
early dissemination mechanisms; these murine findings
are consistent with the presence of disseminated disease
in men with clinically localized PCa (Wood et al. 1994).
The distant metastases in the lungs were stained positive
for GFP, E-cadherin, AR, and phospho-AKT, validating
their prostate origin and epithelial nature (Supplemental
Fig. S3B). PCR genotyping of the Pten allele of microdis-
sected lung metastases from both models further verified
the loss of Pten (Supplemental Fig. S3C). Together, these
findings indicate that TGFBR2 functions as amore potent
tumor suppressor than SMAD4 in the progression of Pten-
null PCa, including metastasis.
In Pten-null PCa, Smad4 deletion results in a dramatic
increase in cell proliferation due to up-regulation of cyclin
D1, which is normally transcriptionally repressed by
SMAD4 in this model; in contrast, no change in the rate
of apoptosis was observed as a function of SMAD4 status
(Ding et al. 2011). We thus compared the tumor biological
impact of SMAD4 andTGFBR2 in the Pten-null PCamod-
el with respect to proliferation (Ki67), apoptosis (cleaved
caspase 3 [CC3]), and cyclin D1 levels (Fig. 2A–C). While
cancer cells in both genotypes showed comparable Ki67
and cyclin D1 staining, cancer cells in the PB-Cre+
PtenL/L Tgfbr2L/L tumors exhibited significantly lower
CC3 staining. The comparable proliferation yet reduced
apoptosis observed in PB-Cre+ PtenL/L Tgfbr2L/L tumors
as compared with PB-Cre+ PtenL/L Smad4L/L tumors
was intriguing, as previous work has shown that TGFβ
can activate JNK and p38MAPK kinase pathways through
SMAD-independent mechanisms to induce apoptosis
(Zhang 2009). Indeed, comparison of JNK, p38 MAPK,
and ERK activation in these two models at 10 wk of age
revealed no differences in phospho-JNK and phospho-
Erk signals (Supplemental Fig. S3D) but did show lower
phospho-p38 MAPK signal in PB-Cre+ PtenL/L Tgfbr2L/L
tumors relative to PB-Cre+ PtenL/L Smad4L/L tumors
Figure 1. TGFBR2 is a more potent tumor suppressor than SMAD4.
(A) Kaplan-Meier curve showing the survival ofmicewith the indicat-
ed genotypes and mouse numbers. The P-value was calculated using
log-rank test. (B) H&E staining of the anterior prostate (AP), dorsolat-
eral prostate (DLP), and ventral prostate (VP). Bar, 200 µm. (C ) Fluo-
rescence images of the indicated organs. Bars: prostate, 5 mm;
lymph nodes, 1 mm; lungs, 2 mm. (D) Quantification of GFP+ lung
micrometastases of the two mTmG models at different ages.
Lu et al.
2338 GENES & DEVELOPMENT
(Fig. 2D). TGFβ-dependent activation of p38 MAPK is
known to be mediated by MAPK kinases such as MKK3/
6 (Zhang 2009), and activated p38 can further phosphory-
late the apoptosis effector Bim (Cai et al. 2006), prompting
us to compare phospho-MKK3/6 and phospho-Bim levels.
PB-Cre+ PtenL/L Tgfbr2L/L tumors exhibit lower phospho-
MKK3/6 and phospho-Bim signals relative to PB-Cre+
PtenL/L Smad4L/L (Fig. 2D; Supplemental Fig. S3E). To-
gether, these data support a model in which attenuated
MKK3/6–p38 MAPK–Bim signaling and consequent re-
duction of apoptosis contribute to the increased aggres-
siveness of PB-Cre+ PtenL/L Tgfbr2L/L tumors relative to
PB-Cre+ PtenL/L Smad4L/L tumors.
TGFBR2 loss enhances PCa seeding and outgrowth
in the bone
In human PCa, the bone is the most common site for dis-
tantmetastasis, prompting comparison of bonemetastasis
potential in our models. As noted above, PB-Cre+ PtenL/L
Tgfbr2L/L mTmGL/+ mice disseminate GFP+ tumor cells
to the lymph nodes and the lungs at a younger age relative
to PB-Cre+ PtenL/L Smad4L/L mTmGL/+ mice (Fig. 1D).
Over the entiremouse life span in these twomodels, there
was no development of overt bone metastasis, although
occasional GFP+ disseminated tumor cells (DTCs) were
present in femoral and tibial bone marrow of late stage
PB-Cre+ PtenL/L Tgfbr2L/L mTmGL/+ and PB-Cre+ PtenL/L
Smad4L/L mTmGL/+ mice (Supplemental Fig. S4A). PCR
genotyping of the Pten allelewas used to confirm the pres-
ence of the DTCs, demonstrating that pooled femoral and
tibial bone marrow from the two models exhibited DTCs
as early as 3 mo of age in the PB-Cre+ PtenL/L Tgfbr2L/L
mice as opposed to 5 mo of age in the PB-Cre+ PtenL/L
Smad4L/L mice (Supplemental Fig. S4B,C).
In a spontaneous tumor model, differences in metastat-
ic kinetics may be the consequence of differences in pri-
mary tumor growth. To study metastatic colonization
directly, we performed the experimental bone metastasis
assay by intratibial inoculation of the same number of
primary cancer cells from PB-Cre+ PtenL/L Tgfbr2L/L
mTmGL/+ and PB-Cre+ PtenL/L Smad4L/L mTmGL/+
mice (Fig. 3A). This assay demonstrated greater bonemet-
astatic burden and reduced survival of mice injected with
PB-Cre+ PtenL/L Tgfbr2L/L mTmGL/+ PCa cells relative to
those injected with PB-Cre+ PtenL/L Smad4L/L mTmGL/+
cells (Fig. 3B–D; Supplemental Fig. S4D). Thus, in this
experimental system, elimination of TGFBR2 provokes
increased metastatic growth potential in the bone micro-
environment relative to elimination of SMAD4. It is
important to note, however, that these results also under-
score that multiple additional genetic events are likely
needed to promote spontaneous metastasis to the bone
in mice, as noted previously (Ding et al. 2012).
The BMP pathway promotes Pten-deficient primary PCa
development
Consistent with the longer survival of PB-Cre+ PtenL/L
Bmpr2L/Lmice relative to PB-Cre+ PtenL/Lmice, magnet-
ic resonance imaging (MRI) and histological analysis
documented slower tumor growth and more benign pa-
thology in the PB-Cre+ PtenL/L Bmpr2L/L mice compared
with age-matched PB-Cre+ PtenL/L controls (Fig. 4A,B).
Consistent with this slower growth rate, PB-Cre+ PtenL/L
Bmpr2L/L prostate tumors contained decreased numbers
of Ki67+ proliferating cells compared with PB-Cre+
PtenL/L tumors in mice of 3–4 mo of age (Supplemental
Fig. S5A,B), yet both genotypes displayed comparable lev-
els of apoptosis (Supplemental Fig. S5A,B). As these
Figure 2. TGFβ signaling restricts PCa partly through the SMAD-in-
dependent apoptosis pathway. (A) IHC staining of Ki67 andCC3 in tu-
mors from11-wk-oldmicewith the indicated genotypes. Bar, 100 µm.
(B) Quantification of the Ki67 and CC3 IHC staining. n = 4. Data rep-
resent mean ± SD. (∗∗∗) P < 0.001; (#) P > 0.05, Student’s t-test. (C ) IHC
staining of cyclin D1 (CCND1) for tumors from 15-wk-old mice with
the indicated genotypes. Bar, 50 µm. (D) Western blot of phospho-p38,
total p38, phospho-Bim, and total Bim for tumors from 10-wk-old
mice with the indicated genotypes.
Figure 3. TGFBR2 loss enhances PCa seeding and outgrowth in the
bone. (A) Schematic illustration of the experimental bone metastasis
procedure. GFP+ cells were isolated using FACS. (B) Survival curve of
NSG mice injected with primary cells isolated from 11-wk-old mice
with the indicated genotypes. n = 5. P-value was calculated by log-
rank test. (C ) X-ray images of the long bones of three representative
mice injected with PCa cells of the indicated genotypes. Bone area de-
marcated with red dotted line indicates bone lesions. (D) Representa-
tive H&E staining at low and high magnification to show the
metastasis burden in mice injected with primary cells isolated from
mice of the indicated genotypes. Bar, 200 µm.
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findings support a role for BMPR2 signaling in promoting
PCa progression, we next explored the role of some of its
ligands with known links to PCa biology. While BMP2,
BMP4, and BMP7 were undetectable by Western blot
analysis in wild-type and PB-Cre+ PtenL/L prostates
(data not shown), BMP6 was expressed at higher levels
in PB-Cre+ PtenL/L prostates compared with wild-type
prostates (Fig. 4C). These murine observations align
with human PCa studies showing elevated BMP6 levels
in the transition from prostate hyperplasia to PCa as
well as a correlation of BMP6 expression with higher
Gleason scores (Barnes et al. 1995; Yuen et al. 2008).
Thus, to secure validation of a role for BMP6 in PCa
cell proliferation in our genetic model, primary PCa cells
derived from PB-Cre+ PtenL/L mice were examined in the
prostatosphere assay in the presence of BMP6 or TGFβ1.
Sphere-forming ability was significantly increased with
BMP6 treatment yet almost completely blocked upon
TGFβ1 treatment (Fig. 4D). On the other hand, primary
PCa cells derived from PB-Cre+ PtenL/L Bmpr2L/L mice
failed to respond to BMP6 (Supplemental Fig. S5C), dem-
onstrating the essential role of BMPR2 in mediating the
BMP6 effect in our model. We also obtained equivalent
results with BMP6 and TGFβ1 in the organoid culture
method (Supplemental Fig. S5D), which better preserves
luminal cell representation in the formed spheres (Chua
et al. 2014).
To better understand BMP pathway function in PCa
progression, we profiled the transcriptome of 6-mo-old
PB-Cre+ PtenL/L and PB-Cre+ PtenL/L Bmpr2L/L tumors
(anterior prostate) using RNA sequencing and detected
361 differentially expressed genes (Fig. 5A; Supplemental
Table S1). Ingenuity Pathway Analysis (IPA) of the most
up-regulated genes in PB-Cre+ PtenL/L tumors compared
with PB-Cre+ PtenL/L Bmpr2L/L tumors showed “role of
osteoblasts, osteoclasts, and chondrocytes in rheumatoid
arthritis” as the top pathway (P-value = 2.89 × 10−6) (Sup-
plemental Fig. S5E; Supplemental Table S2), a finding con-
sistent with the classical function of the BMP pathway in
bone cell homeostasis. As a consequence of BMPR2 loss,
the top-ranked putative master regulator (accounting for
differential gene expression based on the causal network
algorithm in IPA) was BMP2 (P-value = 1.43 × 10−15),
which is an in silico representative of the BMP ligands.
In addition, the canonical BMP pathway was predicted
to be inhibited in PB-Cre+ PtenL/L Bmpr2L/L tumors (Fig.
5B; Supplemental Table S3). Interestingly, inhibition of li-
popolysaccharide-regulated genes was identified as a top
transcriptomic alteration in the Bmpr2 knockout (P-val-
ue = 1.46 × 10−8) using the upstream regulator analysis in
IPA (Fig. 5C). This was because a number of important in-
flammation-related pathways mediated by central signal-
ing regulators, includingNFκB and STAT3,were predicted
Figure 4. BMPR2 deletion delays PCa progression and prolongs
mouse survival. (A) RepresentativeMRI images ofmice of the indicat-
ed genotypes and ages, with prostate outlined by a red contour. (B)
H&E staining of the anterior prostate (AP), dorsolateral prostate
(DLP), and ventral prostate (VP). Bar, 200 µm. (C ) Western blot of
BMP6 and β-actin for the anterior prostate and dorsolateral prostate
of wild type (WT) and PB-Cre+ PtenL/L prostates. (D) Sphere formation
assay using primary tumor cells isolated from PB-Cre+ PtenL/L pros-
tates and treated with BMP6 or TGFβ1. n = 4. Data represent mean
± SD. (∗∗) P < 0.01, Student’s t-test.
Figure 5. The BMP pathway promotes primary PCa progression. (A)
Hierarchical clustering of differentially expressed genes from prostate
tumors of 5-mo-old PB-Cre+ PtenL/L and PB-Cre+ PtenL/L Bmpr2L/L
mice. (B) Causal network of the top master regulator BMP2 generated
by IPA. The overwhelmingly blue colors of the connections and gene
icons indicate that the canonical BMP pathway is predicted to be in-
hibited in PB-Cre+ PtenL/L Bmpr2L/L tumors, consistent with the ac-
tivation z-score being−4.273. (C )Mechanistic network view showing
that the downstream pathways of lipopolysaccharide (i.e., inflamma-
tion related) are broadly inhibited in PB-Cre+ PtenL/L Bmpr2L/L tu-
mors. The graph was generated by IPA. (D) Differential expression
of Ptgs2, Plau, and Angptl4 between the two models, validated using
qRT–PCR with two biological replicates and three technical repli-
cates. (E) Model depicting the antagonistic roles of the TGFβ and
BMP pathways (converged on SMAD4) in Pten-deficient PCa
progression.
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to be inhibited in PB-Cre+ PtenL/L Bmpr2L/L tumors,
based on significant down-regulation of many down-
stream genes of these regulators (Supplemental Table
S4). Some prominent down-regulated genes include pros-
taglandin-endoperoxide synthase 2 (Ptgs2 [also known
as cyclooxygenase-2], down by 12.6-fold), urokinase plas-
minogen activator (Plau [also known as uPA], down by
8.1-fold), and angiopoietin-like 4 (Angptl4, down by 3.8-
fold). The differential expression of these genes was vali-
dated by quantitative RT–PCR (qRT–PCR) (Fig. 5D).
These results suggest that the protumor effect from
BMP signaling in Pten-deficient tumors is likely through
canonical BMP signaling targets as well as targets regulat-
ed by BMP signaling with its emerging role in inflamma-
tion (Ye et al. 2015; Nguyen et al. 2017). Additional
genetic and molecular studies will be needed to define
the role of these gene networks in BMP signaling in
Pten-null PCa.
In summary, this study documents the opposing roles of
the TGFβ and BMP pathways in PCa development in the
context of Pten deficiency. We show that the TGFβ path-
way suppresses PCa development through SMAD4-de-
pendent and SMAD4-independent mechanisms, whereas
BMP signaling promotes PCa progression likely through
both canonical BMP targets and promotion of inflamma-
tion (Fig. 5E). When both pathways are intact, we propose
that the net effect on tumor suppression reflects a domi-
nant role of TGFβ over BMP signaling. Antagonistic inter-
actions between the TGFβ and BMP pathways have been
reported in processes such as chondrogenesis (Keller
et al. 2011), kidney fibrosis (Scherner et al. 2007), and ker-
atinocyte differentiation (McDonnell et al. 2001). Our ge-
netic study reveals the antagonistic cross-talk of the two
pathways in cancer. We stress that the activity of either
TGFβ or BMP signaling in PCa progression depends on
the genetic and environmental context of PCa cells as
well as the stage of the disease. The TGFβ pathway sup-
presses primary andmetastatic PCa progression in the au-
tochthonous Pten deletion model, as shown by us and
others (Bjerke et al. 2014). Meanwhile, TGFβ has been
shown to promote bone metastasis of PCa in immunode-
ficient models (Fournier et al. 2015), suggesting that the
status of other genes (e.g., PTEN and PMEPA1)may deter-
mine the outcome of TGFβ signaling. For BMP signaling,
the specific ligands can dictate the biological effect
because, while BMP6 (Fig. 4D) and BMP4 (Lee et al.
2011; Lin et al. 2017) promote PCa growth in either a
cell-autonomous or a non-cell-autonomous manner,
BMP7 (not detected in PB-Cre+ PtenL/L tumors) inhibits
PCa growth (Kobayashi et al. 2011). The connection of
BMP signaling with genes regulating inflammation is of
particular interest. PB-Cre+ PtenL/L prostate tumors are
infiltrated by myeloid-derived suppressor cells (MDSCs)
(Garcia et al. 2014). In addition, a few genes down-regulat-
ed in PB-Cre+ PtenL/L Bmpr2L/L tumors (e.g., Ptgs2 and
Plau) encode proteins responsible for MDSC recruitment
(Fujita et al. 2011; Ilkovitch et al. 2012). Therefore, it will
be important for future studies to investigate whether
BMP signaling regulates infiltration and function of
MDSCs and other immune cells in PCa. The finding
that ablation of BMP signaling via BMPR2 extinction in
Pten-deficient PCa cells significantly prolongsmouse sur-
vival could have important translational implications, as
it suggests that the BMP pathway may be a therapeutic
target to extend overall survival in a large percentage of
PCa patients.
Materials and methods
Mouse strains
The PB-Cre+ PtenL/L Smad4L/L model was developed previously (Ding
et al. 2011) and backcrossed to the C57BL/6 background for more than
four generations. B6.129S6-Tgfbr2tm1Hlm/N strain was from the National
Cancer Institute Mouse Repository. The B6.129S4(Cg)-Bmpr2tm1.1Enl/
Mmnc strain was from theMutantMouse Resource and ResearchCenters.
mTmG and NSG mice were purchased from Jackson Laboratory. Mice
were maintained in pathogen-free conditions at MD Anderson Cancer
Center. For survival curves, the mice were examined daily, and all mice
with excessive prostate tumor size andmoribund signs, including obstruc-
tion of urination, were euthanized in compliancewith our animal protocol
and considered positive values for survival curves. All manipulations were
approved under the MD Anderson Cancer Center Institutional Animal
Care and Use Committee.
Additional experimental details are in the Supplemental Material.
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